- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 209/42
Total number of patents in this class: 722
10-year publication summary
48
|
48
|
53
|
47
|
52
|
47
|
35
|
43
|
35
|
21
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Achillion Pharmaceuticals, Inc. | 165 |
26 |
Boehringer Ingelheim International GmbH | 4665 |
16 |
Novartis AG | 10856 |
12 |
F. Hoffmann-La Roche AG | 7930 |
12 |
Vertex Pharmaceuticals Incorporated | 1599 |
12 |
Kissei Pharmaceutical Co., Ltd. | 184 |
12 |
Les Laboratoires Servier | 544 |
12 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2847 |
9 |
Allergan, Inc. | 2350 |
8 |
Astellas Pharma Inc. | 1086 |
8 |
Hoffmann-La Roche Inc. | 3408 |
7 |
Glaxosmithkline Intellectual Property (no.2) Limited | 288 |
7 |
Abbvie Inc. | 1805 |
7 |
Vanderbilt University | 1896 |
7 |
FUJIFILM Corporation | 29329 |
6 |
Takeda Pharmaceutical Company Limited | 2714 |
6 |
Oxford University Innovation Limited | 1520 |
6 |
Rutgers, The State University of New Jersey | 1892 |
6 |
Sunshine Lake Pharma Co., Ltd. | 599 |
6 |
Bristol-myers Squibb Company | 4875 |
5 |
Other owners | 532 |